NEW YORK, NY and LONDON, UNITED KINGDOM--(Marketwired - July 13, 2015) - Celsus Therapeutics (CLTX) and Volution Immuno Pharmaceuticals SA today announced that they have entered into a Definitive ...
Celsus Therapeutics and Volution Immuno Pharmaceuticals SA have announced that they have entered into a Definitive Exchange Agreement, pursuant to which privately-held Volution Immuno Pharmaceuticals ...
Celsus Therapeutics will acquire Volution Immuno Pharmaceuticals (VIP), creating a combined company focused on developing and commercializing treatments for orphan autoimmune and inflammatory diseases ...
UCLA is the latest institution to join Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) research program in the U.S. Through the I-O RPM program, BMS and the David Geffen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results